Evidence map›Paper›PMID 35813444›Full record

ArticleComputational and mathematical methods in medicine2022

Potential Diagnostic and Prognostic Values of CBX8 Expression in Liver Hepatocellular Carcinoma, Kidney Renal Clear Cell Carcinoma, and Ovarian Cancer: A Study Based on TCGA Data Mining.

Jie Lin, Lizhu Chen, Dingjie Wu, Jiexiang Lin, Bin Liu, Ciren Guo

Open access · hybridAbstract read
In one paragraph

Article in Computational and mathematical methods in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jie LinDepartment of Gynecology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Jinan District, Fuzhou, Fujian Province, China.ORCID https://orcid.org/0000-0003-0338-6861
Lizhu ChenDepartment of Abdominal Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Jinan District, Fuzhou, Fujian Province, China.ORCID https://orcid.org/0000-0002-9881-2976
Dingjie WuDepartment of Microbial and Biochemical Pharmacy, School of Pharmacy, China Medical University, Shenyang, Liaoning Province, China.ORCID https://orcid.org/0000-0003-3614-0083
Jiexiang LinShengli Clinical Medical College, Fujian Medical University, Fuzhou, China.ORCID https://orcid.org/0000-0002-7212-7583
Bin LiuDepartment of Gynecology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Jinan District, Fuzhou, Fujian Province, China.ORCID https://orcid.org/0000-0003-0340-6084
Ciren GuoDepartment of Gynecology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Jinan District, Fuzhou, Fujian Province, China.ORCID https://orcid.org/0000-0001-5937-5921
Fujian Medical University · CNChina Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chromobox protein homolog 8 (CBX8), a transcriptional repressor, participates in many biological processes in various carcinomas. Cell differentiation, aging, and cell cycle progression are examples of such processes. It is critical to investigate CBX8 expression and its relationship with clinicopathological characteristics in liver hepatocellular carcinoma (LIHC), kidney renal clear cell carcinoma (KIRC), and ovarian cancer (OV) to investigate CBX8's potential diagnostic and prognostic values. Methods: TCGA and CPTAC databases were used to compare the data between cancer and matched normal tissues on RNA and protein expression profiles and their relevant clinical information to determine the relationship between CBX8 and clinicopathological features. Kaplan-Meier analyses were used to assess CBX8 relationship's with disease-free survival (DFS), relapse-free survival (RFS), and overall survival (OS). The multivariate Cox regression analysis was used to identify independent risk factors which affect prognosis. DNA methylation and genetic changes and their impact on prognoses were evaluated by cBioPortal and MethSurv websites. Spearman's correlation was used to determine the relationship of CBX8 expression with somatic mutation. Tumor immune estimation resource (TIMER) was adopted to investigate the relationship between CBX8 and immune cell infiltration (ICI). CBX8-relevant genes and proteins are analyzed by EnhancedVolcano and STRING databases. The gene set enrichment analysis (GSEA) was performed to investigate the potential functions of CBX8. Results: CBX8 RNA and protein overexpression were confirmed in LIHC, KIRC, and OV ( Conclusions: CBX8 could be a potential diagnostic and prognostic biomarker for LIHC, KIRC, and OV cancers.

Indexed as

Carcinoma, HepatocellularCarcinoma, Renal CellKidney NeoplasmsLiver NeoplasmsOvarian NeoplasmsData MiningFemaleHumansKidneyPolycomb Repressive Complex 1PrognosisRNACBX8 protein, humanPolycomb Repressive Complex 1RNA

Identifiers

PMID35813444
PMCPMC9259361
OpenAlexW4285018060

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.